Have a feature idea you'd love to see implemented?
Let us know!

- Stocks
- Healthcare
- NASDAQ: MEIP

Price (delayed)

$3.06

Market cap

$20.39M

P/E Ratio

1.15

Dividend/share

$1.75

EPS

$2.67

Enterprise value

$16.68M

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in

MEI Pharma's debt has shrunk by 100% QoQ and by 100% YoY

MEIP's P/E is 12% below its last 4 quarters average of 1.3

MEIP's net income has surged by 156% year-on-year but it is down by 32% since the previous quarter

The EPS has soared by 156% YoY but it has contracted by 32% from the previous quarter

The company's quick ratio fell by 22% QoQ and by 7% YoY

What are the main financial stats of MEIP

Market
Valuations
Earnings

Shares outstanding

6.66M

Market cap

$20.39M

Enterprise value

$16.68M

Price to earnings (P/E)

1.15

Price to book (P/B)

0.62

Price to sales (P/S)

0.31

EV/EBIT

0.94

EV/EBITDA

0.81

EV/Sales

0.26

Revenue

$65.3M

EBIT

$17.78M

EBITDA

$20.59M

Free cash flow

-$50.48M

Per share
Balance sheet
Liquidity

EPS

$2.67

Free cash flow per share

-$7.58

Book value per share

$4.96

Revenue per share

$9.8

TBVPS

$6.21

Total assets

$41.38M

Total liabilities

$8.36M

Debt

$0

Equity

$33.02M

Working capital

$32.41M

Debt to equity

0

Current ratio

4.88

Quick ratio

4.59

Net debt/EBITDA

-0.18

Margins
Efficiency
Dividend

EBITDA margin

31.5%

Gross margin

100%

Net margin

27.2%

Operating margin

22.3%

Return on assets

24.3%

Return on equity

31.6%

Return on invested capital

25.5%

Return on capital employed

53.8%

Return on sales

27.2%

Dividend yield

57.19%

DPS

$1.75

Payout ratio

65.5%

How has the MEI Pharma stock price performed over time

Intraday

-0.33%

1 week

-0.81%

1 month

8.9%

1 year

-57.02%

YTD

-47.24%

QTD

7.37%

How have MEI Pharma's revenue and profit performed over time

Revenue

$65.3M

Gross profit

$65.3M

Operating income

$14.54M

Net income

$17.78M

Gross margin

100%

Net margin

27.2%

MEIP's net income has surged by 156% year-on-year but it is down by 32% since the previous quarter

MEI Pharma's net margin has surged by 142% YoY but it has decreased by 31% QoQ

The operating income has soared by 140% YoY but it has contracted by 35% from the previous quarter

The operating margin has soared by 130% YoY but it has contracted by 34% from the previous quarter

What is MEI Pharma's growth rate over time

What is MEI Pharma stock price valuation

P/E

1.15

P/B

0.62

P/S

0.31

EV/EBIT

0.94

EV/EBITDA

0.81

EV/Sales

0.26

The EPS has soared by 156% YoY but it has contracted by 32% from the previous quarter

MEIP's P/E is 12% below its last 4 quarters average of 1.3

The stock's price to book (P/B) is 79% less than its 5-year quarterly average of 3.0 but 3.3% more than its last 4 quarters average of 0.6

The equity fell by 35% QoQ but it rose by 34% YoY

MEIP's P/S is 96% below its 5-year quarterly average of 8.2 and 23% below its last 4 quarters average of 0.4

MEIP's revenue is up by 34% YoY but it is down by 2.2% QoQ

How efficient is MEI Pharma business performance

The ROS has soared by 142% YoY but it has contracted by 31% from the previous quarter

The ROE has soared by 136% YoY but it fell by 35% QoQ

MEI Pharma's ROIC has soared by 128% YoY but it has decreased by 16% from the previous quarter

MEIP's return on assets is down by 14% since the previous quarter

What is MEIP's dividend history

DPS

$1.75

Dividend yield

57.19%

Payout ratio

65.5%

Recent dividends

Special dividends are included in TTM DPS and yield

How did MEI Pharma financials performed over time

The total liabilities has plunged by 91% YoY and by 59% from the previous quarter

The total assets has dropped by 66% year-on-year and by 42% since the previous quarter

MEI Pharma's debt is 100% lower than its equity

MEI Pharma's debt to equity has shrunk by 100% QoQ and by 100% YoY

MEI Pharma's debt has shrunk by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.